Readmissions after cytoreductive surgery and HIPEC

John Spiliotis 1, 2 *, George Dadoudis 3, Christos Koupanis 3, Mary Gianniri 2, Pinelopi Stefanopoulou 3, Dimitrios Farmakis 1, Apostolos Raptis 2 and Dimitrios Vaikos 1

1 Department of Surgery/Surg. Oncology European Interbalkan Medical Center, Thessaloniki, Greece.
2 Athens Medical Center, Marousi, Greece.
3 I.C.U, European Interbalcan Medical Center, Thessaloniki, Greece.
 
Research Article
International Journal of Frontiers in Medicine and Surgery Research, 2021, 01(02), 001–004.
Article DOI: 10.53294/ijfmsr.2021.1.2.0059
Publication history: 
Received on 07 July 2021; revised on 23 August 2021; accepted on 25 August 2021
 
Abstract: 
Cytoreductive Surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) results in significant morbidity and mortality and readmission. Previous studies have been limited with numbers or leak of tumor details. We analyzed a 15 year experience a total 730 Hipec procedures and the postoperative morbidity was 22.3% and mortality was 3.6% for the first month after initial operation.
Complications with Dindo classification reached 39% in the first 90 postoperative days. The most common cause of delayed complications which demands re-admission was bowel obstruction and the second is rectovaginal fistulas and pulmonary embolism.
 
Keywords: 
Cytoreductive Surgery; Peritoneal Metastasis; Hyperthermic Intraperitoneal Chemotherapy (HIPEC); Cytoreductive Surgery (CRS)
 
Full text article in PDF: